AngioDynamics ANGO 深 沪
等待开盘 08-25 09:30:00 美东时间
15.58
-0.170
-1.08%
华盛通- 最 高15.745
- 今 开15.73
- 成交量 5.34万股
- 最 低 15.54
- 昨 收 15.75
- 总市值 6.44亿
- 52周最高 16.29
- 市盈率 静 --
- 换手率 0.13%
- 52周最低 9.39
- 委 比 -16.10%
- 总股本 4133.24万
- 历史最高 32.00
- 量 比 0.29
- 振 幅 1.30%
- 历史最低 5.26
- 每 手 1
- 风险率 1.46%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅284.62%！Annexon获Needham上调目标价至25美元；多家大行上调美国银行目标价
今日重点评级关注：Needham：维持Annexon"买入"评级，目标价从11美元升至25美元；Benchmark：维持Prenetics Global"买入"评级，目标价从30美元升至40美元
07-16 18:55
Canaccord Genuity Maintains Buy on AngioDynamics, Raises Price Target to $20
Canaccord Genuity analyst John Young maintains AngioDynamics (NASDAQ:ANGO) with a Buy and raises the price target from $16 to $20.
07-15 22:40
Earnings Scheduled For July 14, 2026
Companies Reporting Before The Bell • Grupo Aeroportuario del (NYSE:PAC) is likely to report quarterly earnings at $3.25 per share on revenue of $862.92 million. • JPMorgan Chase (NYSE:JPM) is projected to report quarterly earnings at $5.59 per share on revenue of $49.39 billion. • Fastenal (NASDAQ:...
07-14 19:11
AngioDynamics Sees FY2027 Adj EPS $(0.29)-$(0.24) vs $(0.16) Est; Sees Sales $336.000M-$341.000M vs $329.600M Est
AngioDynamics (NASDAQ:ANGO) is looking for FY2027 Adj EPS of $(0.29)-$(0.24) vs $(0.16) analyst estimate. sees sales of $336.000 million-$341.000 million vs $329.600 million analyst estimate.
07-14 18:03
AngioDynamics Q4 Adj. EPS $(0.07) Beats $(0.09) Estimate, Sales $86.607M Beat $80.400M Estimate
AngioDynamics (NASDAQ:ANGO) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.09) by 22.22 percent. This is a 133.33 percent decrease over losses of $(0.03) per share from the same period last year. The company reported quarterly sales of $86.607 million...
07-14 18:02
AngioDynamics Q4 2026 Earnings Preview
AngioDynamics (ANGO) is scheduled to announce Q4 earnings results on Tuesday, July 14th, after market close. The consensus EPS Estimate is -$0.09 (-200.0% Y/Y) and the consensus Revenue Estimate is $8...
07-14 05:35
AngioDynamics Says FDA Approves IDE Application To Initiate RELIEF Study Evaluating NanoKnife IRE Platform As Minimally Invasive Treatment Option For Men With Benign Prostatic Hyperplasia
AngioDynamics, Inc. (NASDAQ:ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's...
06-17 20:37
